pertuzumab

  1. K

    USITC Reviews Genentech Complaint Against Biocon Biosimilars

    Washington, March 4 – The U.S. International Trade Commission (USITC) has received a complaint alleging that versions of the cancer drug pertuzumab, which are biosimilars, imported into the United States violate U.S. trade law.Several entities of India’s largest biopharmaceutical company...
  2. M

    India-Brazil Business Forum Sees Key Pharmaceutical MoUs Signed

    New Delhi, February 21 BahiaFarma, Biocon Biologics Ltd, and Bionovis signed a memorandum of understanding (MoU) on Saturday for the development of a medicine.The MoU was signed in the presence of visiting Brazilian President Luiz Inacio Lula da Silva and Commerce and Industry Minister Piyush...
Back
Top